Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Greenwich LifeSciences (GLSI) Enterprise Value (2020 - 2026)

Greenwich LifeSciences filings provide 7 years of Enterprise Value readings, the most recent being -$3.8 million for Q3 2025.

  • Quarterly Enterprise Value rose 34.61% to -$3.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$3.8 million through Sep 2025, up 34.61% year-over-year, with the annual reading at -$4.1 million for FY2024, 41.45% up from the prior year.
  • Enterprise Value hit -$3.8 million in Q3 2025 for Greenwich LifeSciences, down from -$3.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$2.7 million in Q1 2025 and bottomed at -$30.4 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$13.4 million, with a median of -$10.9 million recorded in 2023.
  • The largest annual shift saw Enterprise Value crashed 365.15% in 2021 before it soared 56.75% in 2025.
  • Greenwich LifeSciences' Enterprise Value stood at -$27.2 million in 2021, then surged by 50.49% to -$13.5 million in 2022, then skyrocketed by 48.1% to -$7.0 million in 2023, then surged by 41.45% to -$4.1 million in 2024, then increased by 6.97% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Enterprise Value are -$3.8 million (Q3 2025), -$3.1 million (Q2 2025), and -$2.7 million (Q1 2025).